Abstract
Introduction

Prostate cancer is the most common lethal malignancy diagnosed and the second leading cause of male cancer death in the United
States [1] . Most advanced prostate cancer ultimately progresses to an androgen-independent state resulting in death due to widespread metastases [2] . The [3] . Endostatin, a 20-kD C-terminal fragment of collagen XVIII, inhibits endothelial cell proliferation and tumour angiogenesis [4] and confers survival advantage on cancer patients [5] . But long-term systemic delivery of recombinant protein is expensive, is a painful experience for patients, and may be insufficient to obtain high concentrations of the therapeutic molecule in the tumour tissue [6] . Antiangiogenic gene therapy can overcome the defects and become an effective and promising approach in the treatment of cancer [7] . Recently, we developed a recombinant replicationdefective adenovirus, E10A, that carries the human endostatin gene. E10A has been shown to inhibit tumour growth and angiogenesis in a wide variety of animal tumour models [8, 9] 
Materials and methods
Cell culture
HUVECs were isolated from umbilical cords as described previously [12] and cultured to a passage of [3] [4] [5] [6] [7] 
Recombinant adenoviruses and docetaxel
Replication-defective recombinant adenoviral vectors carrying the human endostatin gene (E10A) and ␤-galactosidase (Ad-LacZ) were generated as described previously [13] . The 
In vitro determination of proliferation
Effect of endostatin and docetaxel either alone or in combination on endothelial cell proliferation was determined by isobolographic analysis as described previously [14] . Recombinant 
Alginate-encapsulated tumour cells assay
Alginate-encapsulated tumour cells assay was performed in vivo as previously described [19, 20] . (Fig. 1C) 
Results
Inhibition of HUVECs proliferation
Evaluation of tumour cell proliferation and apoptosis
Representative tumours harvested from each group were processed for immunohistochemical analyses (Fig. 3A) . Cell proliferation and apoptosis were evaluated using Ki-67 stain and TUNEL method, respectively. Results are shown in Table 1 . (Fig. 4A) . The number of LVD in control tumours was 36 Ϯ 9. LVD was not significantly reduced in tumours of mice treated with docetaxel plus Ad-LacZ (33 Ϯ 12, P Ͼ 0.05), but was in tumours of mice treated with E10A alone or in combination with docetaxel (18 Ϯ 7 and 7 Ϯ 3, respectively; P Ͻ 0.01). Moreover, the tumours that had received combination of E10A and docetaxel showed a greatest marked reduction of LVD (P Ͻ 0.01).
The median number of Ki-67-positive tumour cells counted per 200ϫ field was decreased from 596 in control tumours to 370 after therapy with E10A alone (P Ͻ 0.001). Treatment with docetaxel did not result in a significant reduction in cell proliferation when compared with the control (P ϭ 0.62). The combination of E10A and docetaxel significantly inhibited proliferation compared with the other treatment group (P Ͻ 0.05). The mean number of apoptotic cells counted per 200ϫ field was significantly increased from 6 in Ad-LacZ control tumours to 28, 25 after therapy with E10A or docetaxel plus Ad-LacZ, respectively (P Ͻ 0.001). The tumours from combination exhibited the greatest apoptotic cells in all groups (P Ͻ 0.001).
Inhibition of tumour neovascularization
To investigate whether the antitumour effect is associated with a reduction in the tumour angiogenesis, MVD was determined by CD31-positive cells per 200ϫ field. MVD was not significantly © 2008 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd survival survival rate compared with additional groups of mice included Ad-LacZ control, E10A alone, Ad-LacZ plus docetaxel (P Ͻ 0.001 by log-rank method).
Fig. 2 The effect of combined with E10A and docetaxel on the growth of s.c. xenografts of human prostate cancer in nude mice. When 150-250 mm 3 s.c. xenografts had formed, mice were randomized groups and then subjected to 4 weeks treatment. (A) Time-dependent evolution of tumour volume in athymic mice with PC-3 and DU-145 cells xenografts (n ϭ 10). (B) Tumour weight estimate of antitumour effect (n ϭ 10). Mice were killed after 4 weeks of treatment and tumours were resected and weighted. (C) Kaplan-Meier estimate of survival time (n ϭ 10). Survival of mice injected with E10A in combination with docetaxel had a better
Fig. 3 Immunohistochemical analyses PC-3 s.c. tumours in different treatment groups. (A) The sections were immunostained for expression of Ki-67 (cell proliferation), TUNEL (cell apoptosis) and CD31 (endothelial cells). Representative images were shown (ϫ200). (B) Vessels were stained with rabbit anti-CD31 (red) and anti-mouse ␣-smooth muscle actin (green) to identify whether vessels are mature. Representative images of vessels positive for CD31 (endothelium cells) and ␣-smooth muscle actin (pericytes) were shown (ϫ400). (C) Determination of immature vessels. Ten independent fields at
To evaluate gene expression after combination treatment, we measured serum levels of endostatin in orthotopic tumour-bearing mice treated with E10A and/or docetaxel. Four days after the first injection, serum endostatin levels reached the observed peak. One week after each injection, serum endostatin levels stabilized within a range of 60.7-87.9 ng/ml, which exhibited approximately threefive-fold higher levels, compared with Ad-LacZ group (Fig. 4B) . To determine whether the combination treatment affects proangiogenic environment, VEGF secreted by the tumour cells was measured in the serum. Control group of mice showed 793.8 Ϯ 260.8 pg/ml human VEGF (Fig. 4C) [21] . In addition, antiangiogenic therapy could develop the appearance of 'acquired drug resistance' [22] due to the activation of hypoxia-inducible factor [23] . To improve the efficacy of this form of treatment, combined strategies with other therapies are desirable. In previous studies, antiangiogenic drugs combined with each other [24] [25] [26] , as well as with chemotherapy [17, 27, 28] and radiation [29, 30] [36] . VEGF plays a critical role in tumour angiogenesis and is a potent inducer of dilated, tortuous, disorganized and leaky vasculature in tumours [5] . The abnormal vessels impair the delivery of oxygen and chemotherapeutic agents, which may be one of the causes of tumour resistant to radiotherapy and chemotherapy. Moreover, VEGF induces lymphanaiogenesis to promote cancer metastasis [37] , and has autocrine function acting as a survival factor for tumour cells protecting them from chemotherapy [38] . Therefore Clinical studies of endostatin showed little toxicity at the doses studied with evidence of antitumour effects [45] . Similar results were observed in preclinical toxicity studies [13] and Phase I clinical trails of E10A [21, 46] 
